Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06241183 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Famotidine and Antacids for Treatment of Dyspepsia

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2025 to Dec 31, 2027v4
  2. Secondary endpoints: details revised at 1 of 2 entriesv3
  3. Secondary endpoints: details revised at 2 of 2 entries
    • Study description revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Trial Details
NCT Number NCT06241183
Lead Sponsor Stony Brook University
Conditions
(from sponsor)		 Dyspepsia, GERD, Acid Reflux
Related terms Dyspepsia, Gastroesophageal Reflux
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov